Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.
Antunes
Joana
J
Filipe
Paulo
P
André
Marisa
M
Fraga
Ana
A
Miltenyi
Gabriel
G
Marques Gomes
Manuel
M
D000328:Adult; D004252:DNA Mutational Analysis; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006931:Hyperbaric Oxygenation; D054068:Livedo Reticularis / Q000097:blood / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009154:Mutation; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D011401:Promoter Regions, Genetic; D011516:Prothrombin / Q000235:genetics*; D012867:Skin / Q000473:pathology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D011516:Prothrombin; D010959:Tissue Plasminogen Activator